Joinn Laboratories (China) (HKG:6127) said it expects its 2025 attributable profit to more than triple year on year, according to a Hong Kong bourse filing Tuesday.
Shares of the drug research company gained nearly 1% in late morning trade Wednesday.
The firm expects 232.6 million yuan to 348.9 million yuan in 2025 profit, up 214% to 371% when compared to 2024.
Revenue for the year is expected to decrease 14% to 22% year-on-year to 1.57 billion yuan to 1.74 billion yuan.
The firm expects to report its results by the end of March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments